Eos Management L.P. Acquires Shares of 9,483 Thermo Fisher Scientific Inc. (NYSE:TMO)

Eos Management L.P. acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,483 shares of the medical research company's stock, valued at approximately $4,719,000. Thermo Fisher Scientific makes up about 2.1% of Eos Management L.P.'s portfolio, making the stock its 17th largest position.

Several other hedge funds have also bought and sold shares of the business. Prudent Man Advisors LLC boosted its stake in Thermo Fisher Scientific by 2.2% during the first quarter. Prudent Man Advisors LLC now owns 1,460 shares of the medical research company's stock worth $726,000 after acquiring an additional 32 shares in the last quarter. Wilkinson Global Asset Management LLC boosted its stake in Thermo Fisher Scientific by 0.4% during the first quarter. Wilkinson Global Asset Management LLC now owns 63,985 shares of the medical research company's stock worth $31,839,000 after acquiring an additional 256 shares in the last quarter. Marks Group Wealth Management Inc boosted its stake in Thermo Fisher Scientific by 3.3% during the first quarter. Marks Group Wealth Management Inc now owns 9,387 shares of the medical research company's stock worth $4,671,000 after acquiring an additional 296 shares in the last quarter. TFR Capital LLC. purchased a new position in Thermo Fisher Scientific in the first quarter worth about $475,000. Finally, Rainey & Randall Wealth Advisors Inc. purchased a new position in Thermo Fisher Scientific in the first quarter worth about $269,000. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $4.29 during mid-day trading on Friday, reaching $435.02. The stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The firm has a market cap of $164.22 billion, a price-to-earnings ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The business has a fifty day moving average of $409.39 and a 200 day moving average of $476.23. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company's revenue was up .2% on a year-over-year basis. During the same period in the prior year, the business posted $5.11 earnings per share. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's payout ratio is 10.09%.

Analysts Set New Price Targets

Several brokerages have issued reports on TMO. Argus decreased their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. UBS Group cut shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $500.00 to $460.00 in a report on Tuesday. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a report on Friday. Finally, Royal Bank Of Canada decreased their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $600.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.